Table 2.
Antibacterial compounds in development
| Class | Product | Spectrum | Iv/oral | Indications | Phase | Company (Licensor) |
|---|---|---|---|---|---|---|
| Glycopeptide | Dalbavancin | Gram-positive (excluding VRE) | IV; once-weekly | cSSTI | Phase III | Durata Therapeutics (Pfizer) |
| Glycopeptide | Telavancin | Gram-positive (excluding VRE) | IV | cSSTI and HAP | Marketed for SSTI in USA; HAP approval stalled at FDA | Astellas (Theravance) |
| Glycopeptide | Oritavancin | Gram-positive (including VRE) | IV; single dose treatment | cSSTI | Phase III | The Medicines Company (Lilly) |
| Cephalosporin | Ceftaroline | Gram-positive and gram-negative excluding ESBLs etc. and non-fermenters | IV | SSTI, CAP | Pre-registration | Forest (Cerexa) |
| Glycopeptide-cephalosporin hybrid | TD-1792 | Gram-positive | IV | SSTI, HAP | Phase IIa | Theravance |
| Ketolide | Cethromycin | Gram-positive and respiratory tract infection pathogens | Oral and IV | Community-acquired RTIs biothreat pathogens | Phase III | Advanced Life Sciences (Abbott) |
| Ketolide | EDP-420 | Gram-positive and respiratory tract infection pathogens | Oral | Community-acquired RTIs | Phase II/III | Enanta (Shionogi) |
| Fluoroketolide | Solithromycin | Gram-positive and respiratory tract infection pathogens | IV/oral | Community-acquired RTIs biothreat pathogens | Phase I/II | Cempra (Optimer) |
| Pleuromutilin | BC-3781 | Gram-positive and respiratory tract infection pathogens | Oral IV | Community-acquired RTIs and SSTIs | Phase IIPreclinical | Nabriva |
| Peptide deformylase inhibitor (new class) | GSK1322322 | Gram-positive and Respiratory tract pathogens | Oral | Community-acquired RTIs and SSTIs | Phase I | GlaxoSmithKline |
| Oxazolidinone | Torezolid | Gram-positive (including linezolid- and daptomycin resistant strains) | IV/oral | cSSTI | Phase IIa | Trius (DongA) |
| Oxazolidinone | Radezolid | Gram-positive (including linezolid- and daptomycin resistant strains) | IV/oral | SSTI | Phase IIa | Rib-X |
| Oxazolidinone | PNU-100480 | TB | Oral | TB | Phase I | Pfizer |
| FabI Inhibitor (new class) | AFN-1252 | Staphylococci | Oral | Staph infections | Phase I | Affinium |
| FabI Inhibitor (new class) | MUT056399 | Staphylococci | IV | Staph infections | Phase I | FAB Pharma |
| Aminomethylcycline (tetracycline) | PTK0796 | Gram-positive, RTI and SSTI pathogens | IV/oral | cSSTI, CAP | Phase III | Novartis (Paratek) |
| Fluoroquinolone | Delafloxacin | Broad-spectrum including fluoroquinolone-resistant MRSA | IV/oral | cSSTI, | Phase III | Rib-X |
| Fluoroquinolone | Finafloxacin | Broad-spectrum; enhanced activity at acid pH | Merlion | |||
| Fluoroquinolone | JNJ-Q2 | Enhanced gram-positive activity including fluoroquinolone-resistance-resistant MRSA | IV/oral | Phase I | J&J | |
| Fluorocycline (tetracycline) | TP-434 | Broad gram-positive, -negative and anaerobic activity including Acinetobacter but not P. aeruginosa, less active versus Proteae and some K. pneumoniae | IV/oral | cSSTI, cIAI | Phase I | Tetraphase |
| Aminoglycoside | ACHN-490 | MDR enterobacteriaceae and S. aureus, including aminoglycoside-resistant and metallo-ß-lactamase producers | IV | cUTI, cIAI | Phase I | Achaogen |
| leucyl-tRNA synthase inhibitor (new class) | GSK2251052 | MDR enterobacteriaceae and P. aeruginosa | IV | Anacor/GSK | ||
| Penicillin | CXA-101 | MDR P. aeruginosa and susceptible enterobacteriaceae | IV | cUTI | Phase II | Cubist |
| Penicillin/β-lactamase-inhibitor | CXA-101 /tazobactam (CXA-201) | MDR P. aeruginosa and enterobacteriaceae, excluding metallo-ß-lactamases | IV | cUTI, cIAIVAP | Phase I | Cubist |
| Non-β-lactam β-lactamase-inhibitor (new class) | NXL104 | Class A, C and some class D β-lactamases, including OXA-48 | AstraZeneca (Novexel) | |||
| Cephalosporin/β-lactamase-inhibitor | Ceftaroline/ NXL104 | MRSA and MDR enterobacteriaceae, excluding metallo-ß-lactamases | IV | cUTI, SSTI, CAP | Phase II ready | AstraZeneca/Forest |
| Cephalosporin/β-lactamase-inhibitor | Ceftazidime/ NXL104 | MDR P. aeruginosa and enterobacteriaceae, excluding metallo-ß-lactamases | IV | cUTI, SSTI, VAP | Phase III ready | AstraZeneca/Forest |
| Non-β-lactam β-lactamase-inhibitor (new class) | MK-7655 | Class A and C β-lactamases | Merck & Co | |||
| Carbapenem/β-lactamase-inhibitor | Imipenem/ MK-7655 | MDR P. aeruginosa and enterobacteriaceae, excluding metallo-ß-lactamases; Acinetobacter | IV | cUTI, cIAI, HAP/VAP | Phase II ready | Merck & Co |
| Sulfactam (siderophore monobactam) | BAL30072 | MDR P. aeruginosa Acinetobacter including metallo-ß-lactamases and enterobacteriaceae | IV | Preclinical | Basilea | |
| Monobactam/ carbapenem | BAL30072/ meropenem | Most MDR gram-negatives including resistant Enterobacteriaceae and anaerobes | IV | cUTI, Hospital-acquired cIAI, VAP | Preclinical | Basilea |
| Monocarbam (siderophore monobactam) | MC-1 | MDR P. aeruginosa including metallo-ß-lactamases S. maltophilia and enterobacteriaceae | IV | cUTI, Hospital-acquired cIAI, VAP | Preclinical | Pfizer |
These data are based upon information in the public domain.
Products shaded blue = primarily gram-positive; unshaded = broad(ish)-spectrum; shaded red = MDR gram-negatives.
MDR, multidrug resistant; MRSA, methicillin-resistant Staphylococcus aureus.